PT  - JOURNAL ARTICLE
AU  - Eduardo Listik
AU  - Marcia Listik
AU  - Clarice Listik
AU  - Leny Toma
TI  - AUTISM SPECTRUM DISORDER: A POSSIBLE LINK WITH CHONDROITIN SULFATE
AID  - 10.1101/2020.10.15.20212910
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.15.20212910
4099  - http://medrxiv.org/content/early/2020/10/20/2020.10.15.20212910.short
4100  - http://medrxiv.org/content/early/2020/10/20/2020.10.15.20212910.full
AB  - This study aimed to determine discrepancies in the urinary glycosaminoglycan profiles of autism spectrum disorder (ASD) patients (n=9) when compared with those from healthy volunteers (HVs, n=3). The guardians and/or educators for each participant also returned a validated Autism Behavior Checklist (ABC). The urinary chondroitin sulfate (CS) concentration was 46.1% lower in the ASD group than in the HV group. The ABC score and the urinary CS concentration were negatively correlated (Spearman’s ρ=– 0.2635), indicating that as the severity of the clinical aspect of this disorder increased, the urinary CS concentration decreased. These results suggest that low CS concentrations in the urine may be associated with ASD, and could be measured using a fast and low-cost method for diagnostics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, grant number 2016/18066-6 to LT); and, in part, by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001, including fellowship to EL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures performed in studies involving human participants were approved by Ethics Committee of Research of the Universidade Federal de Sao Paulo (no. 14667219.0.0000.5505) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent/assent was obtained from all participants or their guardians.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are available from the corresponding author, upon reasonable request.All data associated with this study are available from the corresponding author, upon reasonable request.